{
  "docId": "019de073-f2d4-7758-94ad-33c5441d40e0",
  "docSlug": "ecbf51e8e3db999397a90a848caaf022",
  "documentTitle": "BioAtla | Investor Presentation Deck | 40 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 40,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "Data presented in a table format comparing BA3011 (N=13) and BA3011 + Opdivo (N=9).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-f2d4-7758-94ad-33c5441d40e0/20",
  "deckHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0",
  "deckJsonHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0.json",
  "deckAnchorHref": "/decks/019de073-f2d4-7758-94ad-33c5441d40e0#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.58,
        "y": 0.23
      },
      "kind": "list",
      "text": "No treatment-related deaths; Few treatment-related SAEs; Few AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dea8064b-d4ff-4135-8be2-13d88313cdd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.12,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Low-grade constipation observed is consistent with baseline levels seen in advanced cancer patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19c131d3-19b4-43d1-a1eb-e99afa8e1a2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.12,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Interim data- Data cut-off of Oct 25, 2022. CTCAE definitions and footnotes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a421006-42eb-4bb1-b4d6-c3b040cfe8c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.72,
        "w": 0.48,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "table",
      "text": "Adverse events table comparing BA3011 and BA3011 + Opdivo",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04f8033e-fa8d-44fd-97d7-7294b327e88c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fb7a1da-5293-484b-acef-e0d213722c87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Promising safety and tolerability profile emerging in NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bb9d97a-b89f-403e-a217-65de681d9e60",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "694c2195-11af-4429-8d9c-84c281cb47f3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "adaaf91b-c3c7-41d4-a221-86ba71676732",
      "evidence": "The deck presents encouraging Phase 1 and 2 results for BioAtla's CABs",
      "position": 1,
      "objective": "What are the key results and milestones for BioAtla's CABs?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}